Related Experiment Video
Updated: Jul 11, 2026

Osteoclast Derivation from Mouse Bone Marrow
Published on: November 6, 2014
Regulation of global gene expression in the bone marrow microenvironment by androgen: androgen ablation increases
Chang Xu1, Lynn F Graf, Ladan Fazli
1Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.
Background:
Prostate cancer frequently metastasizes to bone. Androgen suppression treatment is initially highly effective, but eventually results in resistant cancer cells. This study evaluates the effects of androgen suppression on the bone and bone marrow (BM). In particular we questioned whether the androgen therapy could adversely facilitate prostate cancer progression through an increase growth factor secretion by the bone microenvironment.
Methods:
Global gene expression is analyzed on mPEDB DNA microarrays. Insulin-like growth factor binding protein-5 (IGFBP5) is detected by immunohistochemistry in mouse tissues and its regulation measured by qPCR and Western blotting in human BM stromal cells. Effects of extracellular matrix-associated IGFBP5 on human prostate epithelial cells are tested in an MTS cell-growth assay.
Results:
Castration increases expression of 159 genes (including 4 secreted cytokines) and suppresses expression of 84 genes. IGFBP5 is most consistently increased and the increase in expression is reversed by testosterone administration. IGFBP5 protein is detected in vivo in osteoblasts, BM stromal cells, and endothelial cells. Primary human stromal cell cultures secrete IGFBP5. In vitro, treatment of immortalized human marrow stromal cells with charcoal-stripped serum increases IGFBP5 mRNA expression, which is reversed by androgen supplementation. IGFBP5 is incorporated into the extracellular matrix. Further, IGFBP5 immobilized on extracellular matrices of stromal cells enhances the growth of immortalized prostate epithelial cells.
Conclusions:
Androgen suppressive therapy increases IGFBP5 in the BM microenvironment and thereby may facilitate the progression of prostate cancer.
Insights
Androgen suppression therapy for prostate cancer increases insulin-like growth factor binding protein-5 (IGFBP5) in bone marrow. This may promote cancer progression by enhancing prostate cancer cell growth within the bone microenvironment.
Area of Science:
- Oncology
- Endocrinology
- Bone Biology
Background:
- Prostate cancer commonly metastasizes to bone.
- Androgen suppression therapy is a primary treatment but leads to resistance.
- The study investigates the impact of androgen suppression on the bone microenvironment and its role in cancer progression.
Purpose of the Study:
- To evaluate the effects of androgen suppression on the bone and bone marrow.
- To determine if androgen therapy facilitates prostate cancer progression via growth factor secretion from the bone microenvironment.
Main Methods:
- Global gene expression analysis using DNA microarrays.
- Immunohistochemistry, qPCR, and Western blotting to detect and measure IGFBP5.
- In vitro cell-growth assays to assess IGFBP5 effects on prostate epithelial cells.
Main Results:
- Androgen suppression altered the expression of numerous genes in the bone marrow.
- Insulin-like growth factor binding protein-5 (IGFBP5) expression significantly increased with castration and decreased with testosterone administration.
- IGFBP5, secreted by bone marrow stromal cells and incorporated into the extracellular matrix, enhanced prostate epithelial cell growth.
Conclusions:
- Androgen suppressive therapy increases IGFBP5 levels within the bone marrow microenvironment.
- Elevated IGFBP5 may contribute to the progression of prostate cancer in bone.
Related Concept Videos
Cell Specific Gene Expression
Genomic Imprinting and Inheritance
The expression of some genes depends on which parent passed the gene to the offspring, through a phenomenon known as...
Master Transcription Regulators
Regulation of Angiogenesis and Blood Supply
Regulation of Hematopoietic Stem Cells
Role of Hematopoietic Growth Factors
Thrombopoietin (TPO), mainly released by the liver,...